Biomunex Signs Exclusive Licensing Agreement With Institut Curie
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
Biomunex Pharmaceuticals, a biopharmaceutical company that develops immunotherapies through the discovery and development of bi- and multi-specific antibodies in cancer treatment, has appointed Dr. Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board.
FRANCE – Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapeutics, and Institut Curie, France’s leading cancer center, have announced a new chapter in their strategic cancer research collaboration.
LAUSANNE, Switzerland, Feb. 16, 2021 /PR Newswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex), Paris, France, of a bispecific antibody targeting two immune checkpoints.
Biomunex Pharmaceuticals, a biopharma company developing immunotherapy through bi- and multi-specific antibodies, and Onward Therapeutics SA, a development stage oncology company, have signed a strategic exclusive worldwide license and development agreement for a bispecific antibody program leveraging Biomunex's next gen bi- and multi-specific antibody platform BiXAb.